Endpoints of hepatitis B treatment
dc.contributor.author | Chotiyaputta, W. | en_US |
dc.contributor.author | Lok, Anna Suk-Fong | en_US |
dc.date.accessioned | 2011-01-31T17:47:47Z | |
dc.date.available | 2011-12-02T15:41:52Z | en_US |
dc.date.issued | 2010-10 | en_US |
dc.identifier.citation | Chotiyaputta, W.; Lok, A. S. F.; (2010). "Endpoints of hepatitis B treatment." Journal of Viral Hepatitis 17(10): 675-684. <http://hdl.handle.net/2027.42/79271> | en_US |
dc.identifier.issn | 1352-0504 | en_US |
dc.identifier.issn | 1365-2893 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/79271 | |
dc.description.abstract | The goal of hepatitis B treatment is to prevent the development of cirrhosis, liver failure, and hepatocellular carcinoma. Ideally, clinical studies should demonstrate that hepatitis B therapies can prevent liver-related complications; however, these clinical endpoints evolve over years or decades. Therefore, clinical trials have relied on intermediate endpoints to evaluate the efficacy of treatment and to determine when treatment can be stopped. Intermediate endpoints that have been used include biochemical, histological, virological, and serological endpoints. This review will discuss the validity of these intermediate endpoints as surrogates of clinical endpoints, and the rates at which these intermediate endpoints can be achieved with currently available therapies. | en_US |
dc.format.extent | 75554 bytes | |
dc.format.extent | 3106 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.subject.other | Alanine Aminotransferase | en_US |
dc.subject.other | HBeAg Seroconversion | en_US |
dc.subject.other | HBsAg Loss | en_US |
dc.subject.other | HBV DNA | en_US |
dc.subject.other | Liver Histology | en_US |
dc.title | Endpoints of hepatitis B treatment | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.identifier.pmid | 20840331 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/79271/1/j.1365-2893.2010.01369.x.pdf | |
dc.identifier.doi | 10.1111/j.1365-2893.2010.01369.x | en_US |
dc.identifier.source | Journal of Viral Hepatitis | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.